Return to ads
All categories


Posted by
Posting ads for 49 years
(Adds comments from FDA consultant in paragraphs 7-9 and updates stock price.) TORONTO (DOW JONES)--Shares of Labopharm Inc.

(DDSS) are lower Monday after the company's Trazodone drug hit a U.S.

regulatory snag.

While the U.S.

Food and Drug Administration's response letter to Labopharm didn't raise any safety or efficacy issues, manufacturing was another matter.

In a release, Labopharm says deficiencies found during an FDA inspection of the active pharmaceutical ingredient manufacturing facility, operated by Angelini of Italy, won't allow the application to be approved in its current form.

The inspection was completed July 3.

Labopharm said Angelini believes the concerns ...
Reply to this ad
Recently viewed ads
Saved ads
Please log in to browse your saved adverts or sign up if you don't have an account yet.
Popular Stuff